Access DB# 154389

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Pamela R Schwartz Examiner #: 61449 Date: 5/25/05
Art Unit: 1774 Phone Number ~~30~~ 21528 Serial Number: 10/701701
Mail Box and Bldg/Room Location: 10C75 Results Format Preferred (circle): PAPER DISK E-MAIL

**If more than one search is submitted, please prioritize searches in order of need.**

**********

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Ink Jet Recording Material

Inventors (please provide full names): Aert, Hubertus; Loccufier, Johan; Lingier, Stefaan

Earliest Priority Filing Date: 11/18/02

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search water soluble/dispersible polymers including monomers of I-II in an ink jet recording context, including the product of the polymer cross-linked with boric acid (see Cl 1).

Elected claims are circled.

SCIENTIFIC REFERENCE BR
Sci & Tech Inf Ctr
MAY 25 RECD
Pat. & T.M. Office

(Structure search covered everything including elected species — not much out close.)

**********

**STAFF USE ONLY**

Searcher: EL
Searcher Phone #:
Searcher Location:
Date Searcher Picked Up:
Date Completed: 6-7-05
Searcher Prep & Review Time:
Clerical Prep Time:
Online Time:

**Type of Search**

NA Sequence (#)
AA Sequence (#)
Structure (#)
Bibliographic
Litigation
Fulltext
Patent Family
Other

**Vendors and cost where applicable**

STN
Dialog
Questel/Orbit
Dr.Link
Lexis/Nexis
Sequence Systems
WWW/Internet
Other (specify)

PTO-1590 (8-01)

Illustrative monomers according to formula (I) are given in Table 1 below:

TABLE 1

| Monomer No. | Structure | Monomer No. | Structure |
|---|---|---|---|
| I-1 |  | I-9 |  |
| I-2 |  | I-10 |  |
| I-3 |  | I-11 Elected |  |
| I-4 |  | I-12 |  |

10/701701 28

WE CLAIM:

1. An ink jet recording material comprising a support and at least one ink receiving layer containing a water-soluble or water-dispersible polymer, wherein said polymer comprises a repeating monomeric unit having a moiety capable of chelating boric acid by means of at least one nitrogen containing functional group and at least one hydroxyl group thereby forming a five- or six-membered ring.

2. Ink jet recording material according to claim 1 wherein said monomeric unit is represented by formula (I):



(I)

wherein,
$R^1$ and $R^2$ are selected independently from the group consisting of hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group;
$L_1$ represents a linking group containing two or three straight chain carbon atoms which may be further substituted or may be part of a ring;
any of $L_1$, $R^1$ and $R^2$ may combine to form a ring, and
at least one of $L_1$, $R^1$ and $R^2$ comprises an ethylenically unsaturated polymerizable group.

3. Ink jet recording material according to claim 2 wherein any of $L_1$, $R^1$ and $R^2$ is substituted by one or more groups comprising one or more additional hydroxyl group, amino groups and amide groups.

4. Ink jet recording material according to claim 1 wherein said polymer comprises at least one other repeating monomeric unit chosen from the list consisting of vinyl acetate, vinyl alcohol, dimethylaminoethyl methacrylate, vinyl amine, vinyl formamide, vinylacetamide, diallyl amine, vinyl versatate, butyral acrylate, styrene, dimethylaminoethyl acrylate, methacryloxyethyltrimethyl ammonium chloride, ethylacrylate, butylmethacrylate, styrene, methyl methacrylate, butyl acrylate,

2-ethylhexyl methacrylate, vinyl amine, diallyldimethyl ammonium chloride, 2-ethylhexyl acrylate, methacryloxyethyldimethyl-benzylammonium chloride, acryloxyethyldimethyl benzyl ammonium chloride, vinyl caprolactam and vinyl pyrrolidone.

5. Ink jet recording material according to claim 1 wherein said polymer is a latex.

6. Ink jet recording material according to claim 1 wherein said polymer functions as binder.

7. Ink jet recording material according to claim 1 wherein said ink receiving layer further comprises a pigment.

8. Ink jet recording material according to claim 7 wherein said pigment is an inorganic pigment.

9. Ink jet recording material according to claim 8 wherein inorganic pigment is chosen from the group consisting of aluminum oxide, boehmite, pseudo-boehmite, gibbsite, bayerite, aluminum hydroxide, silica, clay, calcium carbonate, zirconia, and mixed inorganic oxides/hydroxides.

10. Ink jet recording material according to claim 1 wherein said ink receiving layer further contains a hardener capable of crosslinking said polymer.

11. Ink jet recording material according to claim 10 wherein said hardener is boric acid.

12. An ink jet recording material comprising a support and at least one ink receiving layer containing a water-soluble or water-dispersible polymer, wherein said polymer comprises a repeating monomeric unit represented by formula (II:



(II)

wherein,

$R^1$ and $R^2$ are selected independently from the group consisting of hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted aryl

group, and a substituted or unsubstituted heteroaryl group; $L_2$ represents a linking group containing two or three carbon atoms which may be further substituted or may be part of a ring; any of $L_2$, $R^1$ and $R^2$ may combine to form a ring, and at least one of $L_2$, $R^1$ and $R^2$ comprises an ethylenically unsaturated polymerizable group.

13. Ink jet recording material according to claim 12, wherein $L_2$ is selected from the group consisting of $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH_2CH(CH_3)-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_2OH)-$, $-CH(CH_2OH)CH_2-$, $-CH=CH-$, $-CH=CHCH_2-$, $-C\equiv CCH_2-$, $-CH_2CH=CH-$, $-CH_2C\equiv C-$, $-CH=C(CH_3)-$ and $-C(CH_3)=CH-$.

14. Ink jet recording material according to claim 12 wherein any of $L_2$, $R^1$ and $R^2$ is substituted by one or more groups comprising one or more additional hydroxyl group, amino groups and amide groups.

15. Ink jet recording material according to claim 12 wherein said polymer comprises at least one other repeating monomeric unit chosen from the list consisting of vinyl acetate, vinyl alcohol, dimethylaminoethyl methacrylate, vinyl amine, vinyl formamide, vinylacetamide, diallyl amine, vinyl versatate, butyral acrylate, styrene, dimethylaminoethyl acrylate, methacryloxyethyltrimethyl ammonium chloride, ethylacrylate, butylmethacrylate, styrene, methyl methacrylate, butyl acrylate, 2-ethylhexyl methacrylate, vinyl amine, diallyldimethyl ammonium chloride, 2-ethylhexyl acrylate, methacryloxyethyldimethyl-benzylammonium chloride, acryloxyethyldimethyl benzyl ammonium chloride, vinyl caprolactam and vinyl pyrrolidone.

16. Ink jet recording material according to claim 12 wherein said polymer is a latex.

17. Ink jet recording material according to claim 12 wherein said polymer functions as binder.

18. Ink jet recording material according to claim 12 wherein said ink receiving layer further comprises a pigment.

19. Ink jet recording material according to claim 18 wherein said pigment is an inorganic pigment.

20. Ink jet recording material according to claim 19 wherein inorganic pigment is chosen from the group consisting of aluminum oxide, boehmite, pseudo-boehmite, gibbsite, bayerite, aluminum hydroxide, silica, clay, calcium carbonate, zirconia, and mixed inorganic oxides/hydroxides.

21. Ink jet recording material according to claim 12 wherein said ink receiving layer further contains a hardener capable of crosslinking said polymer.

22. Ink jet recording material according to claim 21 wherein said hardener is boric acid.

23. An ink jet recording material comprising a support and at least one ink receiving layer containing a water-soluble or water-dispersible polymer, wherein said polymer comprises a repeating monomeric unit represented by formula (III):



(III)

wherein,

Z represents the necessary atoms to form a substituted or unsubstituted five- or six-membered heteroring;

$L_3$ represents a linking group containing one or two carbon atoms which may be further substituted or may be part of a ring, and at least one of the heteroring or $L_3$ comprises an ethylenically unsaturated polymerizable group.

24. Ink jet recording material according to claim 23, wherein $L_3$ is selected from the group consisting of $-CH_2CH_2-$, $-CH(CH_3)-$, $-CH=CH-$ and $-C\equiv C-$.

25. Ink jet recording material according to claim 23 wherein $L_3$ is substituted by one or more groups comprising one or more additional hydroxyl group, amino groups and amide groups.

26. Ink jet recording material according to claim 23 wherein a hydrogen atom of $L_3$ is replaced by a substituted or unsubstituted, saturated or unsaturated aliphatic group, a

substituted or unsubstituted aryl group, and a substituted or unsubstituted heteroaryl group.

27. Ink jet recording material according to claim 23 wherein said polymer comprises at least one other repeating monomeric unit chosen from the list consisting of vinyl acetate, vinyl alcohol, dimethylaminoethyl methacrylate, vinyl amine, vinyl formamide, vinylacetamide, diallyl amine, vinyl versatate, butyral acrylate, styrene, dimethylaminoethyl acrylate, methacryloxyethyltrimethyl ammonium chloride, ethylacrylate, butylmethacrylate, styrene, methyl methacrylate, butyl acrylate, 2-ethylhexyl methacrylate, vinyl amine, diallyldimethyl ammonium chloride, 2-ethylhexyl acrylate, methacryloxyethyldimethyl-benzylammonium chloride, acryloxyethyldimethyl benzyl ammonium chloride, vinyl caprolactam and vinyl pyrrolidone.

28. Ink jet recording material according to claim 23 wherein said polymer is a latex.

29. Ink jet recording material according to claim 23 wherein said polymer functions as binder.

30. Ink jet recording material according to claim 23 wherein said ink receiving layer further comprises a pigment.

31. Ink jet recording material according to claim 30 wherein said pigment is an inorganic pigment.

32. Ink jet recording material according to claim 31 wherein inorganic pigment is chosen from the group consisting of aluminum oxide, boehmite, pseudo-boehmite, gibbsite, bayerite, aluminum hydroxide, silica, clay, calcium carbonate, zirconia, and mixed inorganic oxides/hydroxides.

33. Ink jet recording material according to any of claims 23 wherein said ink receiving layer further contains a hardener capable of crosslinking said polymer.

34. Ink jet recording material according to claim 33 wherein said hardener is boric acid.

```
=> file reg
FILE 'REGISTRY'
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)



=> d his


     FILE 'HCAPLUS'
L1            12 S AERT ?/AU
L2            90 S LOCCUFIER ?/AU
L3            54 S LINGIER ?/AU
L4             0 S L1 AND L2 AND L3
L5             0 S L1 AND L2
L6             0 S L1 AND L3
L7             9 S L2 AND L3
                 SEL L7 1-9 RN

     FILE 'REGISTRY'
L8           158 S E1-E158
L9           120 S L8 AND N/ELS AND O/ELS
L10           67 S L9 AND 4/ELC.SUB
L11           16 S L10 AND 1/N

     FILE 'LREGISTRY'
L12              STR

     FILE 'REGISTRY'
L13              SCR 970 AND 1700
L14              SCR 1839
L15           50 S L12 AND L13 NOT L14
L16              SCR 1199
L17           50 S L12 AND L13 NOT (L14 OR L16)
L18              SCR 1602
L19           50 S L12 AND L13 NOT (L14 OR L16 OR L18)
L20         1839 S L12 AND L13 NOT (L14 OR L16 OR L18) FUL
                 SAV L20 SCH701/A
L21           30 S L20 AND PMS/CI
                 E BORIC ACID/CN
L22            2 S E3
                 SEL L22 1-2 RN
                 EDIT E1-E2 /BI /CRN
L23         1671 S E1-E2
L24            0 S L23 AND L20
```

```
     FILE 'HCA'
L25         3911 S L20
L26        57104 S L22 OR L23 OR BORIC#(A)ACID# OR B(W)OH(W)3 OR H3BO3
L27           27 S L21
L28            0 S L27 AND L26
L29           10 S L25 AND L26

     FILE 'REGISTRY'
                E C13H19NO3
L30         3349 S E3
L31           19 S L30 AND L20
                E C12H17NO3
L32         3426 S E3
L33            4 S L32 AND L20

     FILE 'REGISTRY'


=> d l20 que stat
L12                STR

CH2=C              N~G1-OH
1   2              5   6   7


REP G1=(2-3) CH
NODE ATTRIBUTES:
CONNECT IS M2  RC AT   2
CONNECT IS M2  RC AT   5
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   5

STEREO ATTRIBUTES: NONE
L13                SCR 970 AND 1700
L14                SCR 1839
L16                SCR 1199
L18                SCR 1602
L20          1839 SEA FILE=REGISTRY SSS FUL L12 AND L13 NOT (L14 OR L16 OR
                  L18)

100.0% PROCESSED   3357 ITERATIONS                      1839 ANSWERS
SEARCH TIME: 00.00.01
```

=> file hca
FILE 'HCA'


=> d l29 1-10 all hitstr

L29 ANSWER 1 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 139:297121 HCA
ED Entered STN: 30 Oct 2003
TI Ammonium hydrogencarbonate, an excellent buffer for the analysis of basic drugs by liquid chromatography-mass spectrometry at high pH
AU Espada, Alfonso; Rivera-Sagredo, Alfonso
CS European Analytical Technologies, DCR&T Alcobendas, Lilly S.A., Alcobendas, 28108, Spain
SO Journal of Chromatography, A (2003), 987(1-2), 211-220
CODEN: JCRAEY; ISSN: 0021-9673
PB Elsevier Science B.V.
DT Journal
LA English
CC 64-3 (Pharmaceutical Analysis)
AB Ammonium hydrogencarbonate buffer has been found to be esp. useful for high-pH HPLC anal. of samples from both combinatorial and medicinal chem. sources. Satisfactory results were obtained by the std. diode array, evaporative light-scattering, and MS detection by using this buffer at a concn. of 10 mM. From a practical standpoint, ammonium hydrogencarbonate is an ideal buffer for chromatog. since it provides excellent chromatog. behavior and reproducible sepn. In addn. to this, its volatility makes it an essential tool for rapid LC-MS product identification. Ammonium hydrogencarbonate was tested for a no. of drug-like compds. analyzed as mixts., and data obtained were compared to those from the classical and MS-friendly buffers widely used by chromatog.: trifluoroacetic and formic acids. The results of this study revealed the suitability of this buffer for routine HPLC application in research labs.
ST drug sepn HPLC MS solvent effect; liq chromatog sepn basic drug
IT Buffers
HPLC
Mass spectrometry
Pharmaceutical analysis
Solvent effect
(sepn. of basic drugs by HPLC using mass spectroscopy detection and buffer system optimization)

IT 51-06-9, Procainamide 52-53-9, Verapamil 58-32-2, Dipyridamole 525-66-6, Propranolol 3416-26-0, Lidoflazine **6452-71-7**, Oxprenolol 13523-86-9, Pindolol 21829-25-4, Nifedipine 42399-41-7, Diltiazem 52468-60-7, Flunarizine
(sepn. of basic drugs by HPLC using mass spectroscopy detection and buffer system optimization)

IT 56-40-6, Glycine, analysis 77-86-1, Tris buffer 109-02-4, 4-Methylmorpholine 109-89-7, Diethylamine, analysis 121-44-8, Triethylamine, analysis 123-75-1, Pyrrolidine, analysis 463-79-6, Carbonic acid, analysis 626-67-5, 1-Methylpiperidine 1066-33-7, Ammonium hydrogencarbonate 7664-41-7, Ammonia, analysis **10043-35-3**, **Boric acid**, analysis
(sepn. of basic drugs by HPLC using mass spectroscopy detection and buffer system optimization)

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bosch, G; personal communication 2000
(2) Buszewski, B; J High Resolut Chromatogr 1998, V21, P267 HCA
(3) Canals, I; Anal Chem 2001, V73, P4937 HCA
(4) Chandler, C; J Chromatogr 1986, V358, P179 HCA
(5) Choi, B; LC.cntdot.GC North Am 2002, V2, P152
(6) Claessens, H; J Chromatogr A 1996, V728, P259 HCA
(7) Dolan, J; LC.cntdot.GC Eur 2001, V12, P1132
(8) Dolle, R; J Comb Chem 2000, V2, P383 HCA
(9) Espada, A; unpublished results 2001
(10) Espinosa, S; J Chromatogr A 2002, V947, P47 HCA
(11) Fang, L; J Comb Chem 2000, V2, P254 HCA
(12) Gorden, E; J Med Chem 1994, V37, P1385
(13) Gordon, E; Combinatorial Chemistry and Molecular Diversity in Drug Discovery 1999
(14) Hayward, M; presented at 47th ASMS symposium 1999
(15) Hsu, B; J Chromatogr B 1999, V725, P103 HCA
(16) Kuhlmann, F; J Am Soc Mass Spectrom 1995, V6, P1221 HCA
(17) McKeown, A; J Sep Sci 2001, V24, P835 HCA
(18) Merck & Co; Merck Index, 12th ed 1996
(19) Mutton, I; Chromatographia 1998, V69, P291
(20) Needham, S; J Chromatogr A 2000, V869, P159 HCA
(21) Neue, U; Am Lab 2001, V12, P51
(22) Neue, U; J Chromatogr A 1999, V849, P101 HCA
(23) Petritis, K; LC.cntdot.GC Eur 2002, V2, P98
(24) Pietta, P; J Chromatogr 1981, V210, P516 HCA
(25) Sandra, P; LC.cntdot.GC Eur 2001, V12, P8
(26) Shah, N; J Comb Chem 2000, V2, P453 HCA
(27) Snyder, L; Practical HPLC Method Development, 2nd ed 1997, P210
(28) Thompson, L; Chem Rev 1996, V96, P555 HCA
(29) Vervoort, R; J Chromatogr A 2001, V931, P67 HCA
(30) Wehr, T; LC.cntdot.GC North Am 2002, V1, P40
(31) Wilson, N; LC.cntdot.GC Eur 2001, V7, P360

(32) Yurek, D; J Comb Chem 2002, V4, P138 HCA
(33) Zhao, J; J Mass Spectrom 2002, V37, P421 HCA

IT **6452-71-7**, Oxprenolol
(sepn. of basic drugs by HPLC using mass spectroscopy detection and buffer system optimization)

RN 6452-71-7 HCA

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-(9CI) (CA INDEX NAME)



IT **10043-35-3**, **Boric acid**, analysis
(sepn. of basic drugs by HPLC using mass spectroscopy detection and buffer system optimization)

RN 10043-35-3 HCA

CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



L29 ANSWER 2 OF 10 HCA COPYRIGHT 2005 ACS on STN

AN 137:15223 HCA

ED Entered STN: 04 Jul 2002

TI Quantitative determination of oxprenolol and timolol in urine by capillary zone electrophoresis

AU Maguregui, M. I.; Jimenez, R. M.; Alonso, R. M.; Akesolo, U.

CS Departamento de Pintura, Facultad de Bellas Artes, Universidad del Pais Vasco, Bilbao, 48080, Spain

SO Journal of Chromatography, A (2002), 949(1-2), 91-97
CODEN: JCRAEY; ISSN: 0021-9673

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-1 (Pharmacology)
Section cross-reference(s): 64

AB A simple capillary zone electrophoretic method with UV detection was developed for the quant. detn. of the .beta.-adrenoreceptor antagonists (.beta.-blockers) oxprenolol and timolol in human urine, preceded by a solid-phase extn. step. The electrophoretic sepn. was

performed on a 78 cm.times.75 .mu.m I.D. fused-SiO2 capillary (effective capillary length: 70 cm). The electrolyte consisted of a Na2B4O7-**H3BO3** (50 mM), pH 9. The introduction of the sample was made hydrostatically for 20 s and the running voltage 25 kV at the injector end of the capillary. Photometric detection was used at a wavelength of 229 nm for oxprenolol and 280 nm for timolol. Under these conditions oxprenolol migrated at 4.76 .+-. 0.05 min and timolol at 4.97 .+-. 0.05 min. The solid-phase extn. methods were optimized for each .beta.-blocker and provided recoveries of 72.8% for timolol and 94.52% for oxprenolol. Good resoln. from the endogenous compds. present in the urine matrix were achieved for both compds. The method was applied to the detn. of both .beta.-blockers in pharmaceutical formulations and urine samples obtained from hypertensive patients after the ingestion of a therapeutic dose (in a 24-h time interval after the ingestion). The quant. results were compared with results previously obtained at the authors' labs. by HPLC and are in good agreement. Good reproducibility, linearity, accuracy and quantitation limits (in urine) of 0.19 .mu.g/mL for timolol and 0.20 .mu.g/mL for oxprenolol were obtained, allowing the method to be applied to pharmacokinetic studies of these compds.

ST oxprenolol timolol detn urine pharmaceutical CZE

IT Capillary zone electrophoresis
Urine analysis
(quant. detn. of oxprenolol and timolol in urine by capillary zone electrophoresis)

IT 26921-17-5, Blocadren 263412-94-8, Transitensin
(quant. detn. of oxprenolol and timolol in urine and pharmaceuticals by capillary zone electrophoresis)

IT **6452-71-7**, Oxprenolol 26839-75-8, Timolol
(quant. detn. of oxprenolol and timolol in urine by capillary zone electrophoresis)

RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bai, X; Electroanalysis 2000, V12(17), P1379 HCA
(2) Black, S; J Chromatogr B 1996, V685, P67 HCA
(3) De Jong, E; Trend Anal Chem 1988, V7(10), P375 HCA
(4) Gluth, W; Pharmazie 1991, V46, P336 HCA
(5) Hyoetylaeinen, T; J Chromatogr Sci 1997, V35, P280
(6) Katayama, M; Anal Lett 2001, V34(1), P91 HCA
(7) Kintz, P; J Forensic Sci 2000, V45(1), P170 HCA
(8) Li, F; J Chromatogr B 1995, V674, P277 HCA
(9) Litter, M; Farmacologia Experimental y Clinica 1986
(10) Lukkari, P; J Chromatogr 1993, V632, P143 HCA
(11) Lukkari, P; J Chromatogr A 1994, V674, P241 HCA
(12) Maguregui, M; J Chromatogr B 1995, V674, P85 HCA
(13) Maguregui, M; J Chromatogr Sci 1998, V36, P516 HCA
(14) Maguregui, M; J Liq Chromatogr Rel Technol 1996, V19(10), P1643 HCA

(15) Marko, V; Determination of ss-blockers in Biological Material 1989
(16) Martinez, V; J Liq Chromatogr Rel Technol 2000, V23, P467 HCA
(17) Martinez, V; J Pharm Biomed Anal 2000, V23, P459 HCA
(18) Masucci, J; J Chromatogr A 1998, V810, P95 HCA
(19) Mazzo, D; Anal Prof Drug Subs 1987, V16, P642
(20) Rao, K; J Chromatogr 1988, V426, P229
(21) Ye, L; Anal Chim Acta 1987, V196, P255

IT **6452-71-7**, Oxprenolol
(quant. detn. of oxprenolol and timolol in urine by capillary zone electrophoresis)

RN 6452-71-7 HCA

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-(9CI) (CA INDEX NAME)



L29 ANSWER 3 OF 10 HCA COPYRIGHT 2005 ACS on STN

AN 133:301171 HCA

ED Entered STN: 09 Nov 2000

TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents

IN Chen, Feng-jing; Patel, Manesh V.

PA Lipocine, Inc., USA

SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K009-14
ICS A61K009-48; A61K009-64; A61K009-66; A01N025-00

CC 63-6 (Pharmaceuticals)

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2000059475 | A1 | 20001012 | WO 2000-US7342 | 200003 16 |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO,

RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6383471 B1 20020507 US 1999-287043 19990406

CA 2366702 AA 20001012 CA 2000-2366702 20000316

EP 1165048 A1 20020102 EP 2000-916547 20000316
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC,
PT, IE, SI, LT, LV, FI, RO

PRAI US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| WO 2000059475 | ICM | A61K009-14 |
| | ICS | A61K009-48; A61K009-64; A61K009-66; A01N025-00 |
| WO 2000059475 | ECLA | A61K009/107D; A61K047/02 |
| US 6383471 | NCL | 424/045.000; 424/046.000; 424/401.000; 424/436.000; 424/451.000; 514/944.000 |
| | ECLA | A61K009/107D; A61K047/02 |

AB The present invention is directed to a pharmaceutical compn. including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of prepg. such compns. by providing a compn. of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier contg. concd. phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole soln. upon diln. in simulated gastric fluid.

ST hydrophobic drug carrier base surfactant triglyceride

IT Diglycerides
Diglycerides
Diglycerides
Glycerides, biological studies
Glycerides, biological studies

Glycerides, biological studies
Monoglycerides
Monoglycerides
Monoglycerides
(C8-10 monoglycerides and diglycerides; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies
(C8-10, esters with propylene glycol; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies
(C8-10, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies
(C8-10; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Hydroquinones
(Hydroquinosulfonic acid; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Monoglycerides
(acetates, with C6 to C20 fatty acid; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(aerosols; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Amines, biological studies
(aliph.; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Sulfonates
(alkanesulfonates; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Phenols, biological studies
(alkyl, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Glycosides
(alkyl, maltosides; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Fats and Glyceridic oils, biological studies

(almond, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Sulfones
(amino; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Heterocyclic compounds
Heterocyclic compounds
(arom., hydroxy; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Amines, biological studies
(arom.; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(capsules; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(carriers; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies
(corn, ethoxylated, Crovol M 40 and Crovol M 70; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies
(essential; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Fatty acids, biological studies
(esters, with polyglycerol; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Amino acids, biological studies
(esters; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Carbohydrates, biological studies
(ethers; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Castor oil
(ethoxylated, Incrocas 35 and Incrocas 40; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Sterols
(ethoxylated; Nikkol BPS-30, pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Corn oil
Fatty acids, biological studies
Glycerides, biological studies
Olive oil
Palm kernel oil
Peanut oil
Sterols
(ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(gels; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Aromatic compounds
Aromatic compounds
(heterocyclic, hydroxy; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Amines, biological studies
(heterocyclic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Castor oil
(hydrogenated, ethoxylated, Cremophor RH 40; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Castor oil
Palm kernel oil
(hydrogenated, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Surfactants
(hydrophilic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Surfactants
(hydrophobic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Minerals, biological studies
(hydrotalcite-group; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Acids, biological studies
(inorg.; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Surfactants
(ionic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(lotions; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(mucosal; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Fatty acids, biological studies
(non-essential; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Surfactants
(nonionic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(ointments, creams; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(ointments; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(ophthalmic; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(oral; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Acids, biological studies
(org.; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Glycerides, biological studies
(palm kernel-oil, ethoxylated, Crovol PK 70; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Drug delivery systems
(parenterals; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(pastes; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Surfactants
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Alcohols, biological studies
Amino acids, biological studies
Bile salts
Carboxylic acids, biological studies
Diglycerides
Phenols, biological studies
Phospholipids, biological studies
Soybean oil
Sulfonamides
Sulfonates
Sulfonic acids, biological studies
Sulfonylureas
Tannins
Thiols (organic), biological studies
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Sterols
(phyto; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Alcohols, biological studies
(polyhydric, reaction products; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Alcohols, biological studies
(polyhydric, solubilizer; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(pulmonary; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(rectal; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and

triglycerides)
IT Fatty acids, biological studies
(salts; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(solns., oral; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Amides, biological studies
Esters, biological studies
Polyoxyalkylenes, biological studies
(solubilizer; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Sterols
(soya, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(sprays; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Carbohydrates, biological studies
(sugar esters; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(suppositories; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(topical; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(transdermal; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Drug delivery systems
(vaginal; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Fats and Glyceridic oils, biological studies
(vegetable, ethoxylated; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)
IT Fats and Glyceridic oils, biological studies

(vegetable, hydrogenated, Sterotex NF; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT Glycerides, biological studies
Monoglycerides
(with C6 to C20 fatty acid; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 53824-77-4, Propylene glycol dicaprate
(Captex 100; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 9004-96-0, Polyethylene glycol monooleate
(Crodet O 40, Kessco PEG 1000MO; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 79665-92-2, Hexaglycerol monooleate
(Drewpol 6-1O; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 9004-81-3, Kessco PEG 1000ML
(Kessco PEG 1000ML and Mapeg 200ML; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 9005-02-1, Polyethylene glycol dilaurate
(Kessco PEG 1540DL; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 9005-07-6, Polyethylene glycol dioleate
(Kessco PEG 1540DO; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 50-06-6, Phenobarbital, biological studies 50-21-5, biological studies 50-21-5D, Lactic acid, glycerides 50-44-2, Mercaptopurine 50-48-6, Amitriptyline 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-55-5, Reserpine 50-78-2 50-81-7, Ascorbic acid, biological studies 51-48-9, Levothyroxine, biological studies 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-64-9, Dexamphetamine 52-86-8, Haloperidol 53-86-1, Indomethacin 54-05-7, Chloroquine 54-11-5, Nicotine 54-31-9 56-54-2, Quinidine 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-22-7, Vincristine 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-43-2, Amylobarbital 57-44-3, Barbital 57-47-6, Physostigmine 57-66-9, Probenecid 57-88-5, Cholesterol, biological studies 58-14-0, Pyrimethamine 58-25-3, Chlordiazepoxide 58-32-2, Dipyridamole 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-54-8, Ethacrynic acid 58-73-1,

Diphenhydramine 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-66-5, Acetazolamide 59-87-0, Nitrofurazone 59-96-1, Phenoxybenzamine 61-56-3, Sulthiame 61-68-7, Mefenamic acid 61-72-3, Cloxacillin 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 64-77-7, Tolbutamide 65-85-0, Benzoic acid, biological studies 66-76-2, Dicumarol 66-79-5, Oxacillin 67-20-9, Nitrofurantoin 68-04-2, Sodium Citrate 68-11-1, Thioglycolic acid, biological studies 68-35-9, Sulfadiazine 69-23-8, Fluphenazine 69-72-7, biological studies 69-93-2, Uric acid, biological studies 72-44-6, Methaqualone 72-69-5, Nortriptyline 74-55-5, Ethambutol 75-75-2, Methanesulfonic acid 76-57-3, Codeine 76-74-4, Pentobarbital 76-99-3, Methadone 77-28-1, Butobarbital 77-36-1, Chlorthalidone 77-86-1, Tromethamine 77-92-9, biological studies 79-09-4, Propanoic acid, biological studies 79-10-7, Acrylic acid, biological studies 82-92-8, Cyclizine 83-68-1, Vitamin K6 83-69-2, Vitamin K7 83-70-5, Vitamin K5 83-89-6, Mepacrine 86-21-5, Pheniramine 86-22-6, Brompheniramine 86-35-1, Ethotoin 86-42-0, Amodiaquine 87-69-4, biological studies 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 90-82-4, Pseudoephedrine 90-84-6, Diethylpropion 94-20-2, Chlorpropamide 97-23-4, Dichlorophen 99-66-1, Valproic acid 101-31-5, Hyoscyamine 102-71-6, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, 1,2-Ethanediamine, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Butanedioic acid, biological studies 110-16-7, 2-Butenedioic acid (2Z)-, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-03-5, Glyceryl monooleate 111-62-6, Ethyl Oleate 111-90-0, Transcutol 112-80-1, Oleic acid, biological studies 113-15-5, Ergotamine 113-45-1, Methylphenidate 113-59-7, Chlorprothixene 113-92-8 114-07-8, Erythromycin 115-38-8, Methylphenobarbital 117-89-5, Trifluoperazine 121-44-8, biological studies 122-09-8, Phentermine 122-20-3, Triisopropanolamine 124-04-9, Hexanedioic acid, biological studies 125-28-0, Dihydrocodeine 125-53-1, Oxyphencyclimine 125-84-8, Aminoglutethimide 127-09-3, Sodium Acetate 127-33-3, Demeclocycline 127-69-5, Sulfafurazole 127-71-9, Sulfabenzamide 127-79-7, Sulfamerazine 128-13-2, Ursodeoxycholic acid 128-37-0, Butylated Hydroxytoluene, biological studies 129-03-3, Cyproheptadine 129-20-4, Oxyphenbutazone 130-95-0, Quinine 132-17-2, Benztropine 138-36-3, p-Bromophenylsulfonic acid 139-33-3, Edetate Disodium 141-43-5, biological studies 142-18-7, Glyceryl monolaurate 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 144-11-6, Benzhexol 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Ethanedioic acid, biological studies 144-80-9, Sulfacetamide 144-83-2, Sulfapyridine 145-42-6, Taurocholic acid, sodium salt 146-22-5, Nitrazepam 146-54-3,

Fluopromazine 148-79-8, Thiabendazole 151-21-3, Sodium Dodecyl Sulfate, biological studies 154-42-7, Thioguanine 190-39-6, Bisanthene 288-14-2, Isoxazole 298-57-7, Cinnarizine 299-42-3, Ephedrine 300-62-9, Amphetamine 302-79-4, Tretinoin 305-03-3, Chlorambucil 321-64-2, Tacrine 359-83-1, Pentazocine 361-37-5, Methysergide 364-62-5, Metoclopramide 389-08-2 396-01-0, Triamterene 404-86-4, Capsaicin 437-38-7, Fentanyl 439-14-5, Diazepam 442-52-4, Clemizole 443-48-1, Metronidazole 446-86-6, Azathioprine 458-24-2, Fenfluramine 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 486-16-8, Carbinoxamine 500-92-5, Proguanil 511-12-6, Dihydroergotamine 514-65-8, Biperiden 519-23-3, Ellipticine 522-00-9, Ethopropazine 523-87-5, Dimenhydrinate 525-66-6 526-95-4, D-Gluconic acid 536-33-4, Ethionamide 537-21-3, Chlorproguanil 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 548-73-2, Droperidol 561-27-3, Diamorphine 564-25-0, Doxycycline 569-65-3, Meclozine 577-11-7, Docusate sodium 599-79-1, Sulfasalazine 603-50-9, Bisacodyl 604-75-1, Oxazepam 631-61-8, Ammonium Acetate 644-62-2, Meclofenamic acid 657-24-9, Metformin 668-94-0, 4,5-Diphenylimidazole 671-16-9, Procarbazine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 739-71-9, Trimipramine 745-65-3, Alprostadil 768-94-5, Amantadine 846-49-1, Lorazepam 846-50-4, Temazepam 848-75-9, Lormetazepam 865-21-4, Vinblastine 911-45-5, Clomiphene 915-30-0, Diphenoxylate 961-71-7, Phenbenzamine 968-81-0, Acetohexamide 1134-47-0, Baclofen 1156-19-0, Tolazamide 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium Hydroxide, biological studies 1310-73-2, Sodium Hydroxide, biological studies 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol oleate 1333-28-4, Undecenoic acid 1335-30-4, Aluminum silicate 1336-21-6, Ammonium Hydroxide 1338-39-2, Sorbitan monolaurate 1338-41-6, Sorbitan monostearate 1338-43-8, Sorbitan monooleate 1400-61-9, Nystatin 1404-90-6, Vancomycin 1406-05-9, Penicillin 1508-75-4, Tropicamide 1553-60-2, Ibufenac 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1812-30-2, Bromazepam 1951-25-3, Amiodarone 1972-08-3, Dronabinol 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2078-54-8, Propofol 2447-57-6, Sulfadoxine 2487-39-0, Vitamin K-S (II) 2515-61-9, 1,5-Diphenylpyrazoline 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2998-57-4, Estramustine 3056-17-5, Stavudine 3116-76-5, Dicloxacillin
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 3239-44-9, Dexfenfluramine 3737-09-5, Disopyramide 4117-33-3, Lysine Ethyl Ester 4342-03-4, Dacarbazine 4759-48-2, Isotretinoin 5002-47-1, Fluphenazine decanoate 5036-02-2,

Tetramisole 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5306-85-4, Dimethyl Isosorbide 5588-33-0, Mesoridazine 5633-20-5, Oxybutynin 5786-21-0, Clozapine **6452-71-7**, Oxprenolol 6493-05-6, Pentoxifylline 6506-37-2, Nimorazole 7087-68-5, Diisopropylethylamine 7261-97-4, Dantrolene 7416-34-4, Molindone 7647-01-0, Hydrochloric Acid, biological studies 7664-38-2, Phosphoric acid, biological studies 7664-38-2D, Phosphoric acid, esters, biological studies 7664-93-9, Sulfuric acid, biological studies 7681-93-8, Natamycin 7689-03-4, Camptothecin 7697-37-2, Nitric acid, biological studies 7778-53-2, Potassium Phosphate 8007-43-0, Sorbitan sesquioleate 8045-34-9, Pentaerythritol stearate 9002-92-0, Polyoxyethylene lauryl ether 9002-93-1 9002-96-4, D-.alpha.-Tocopheryl polyethylene glycol succinate 9004-74-4, Methoxy polyethylene glycol 9004-95-9, Polyethylene glycol cetyl ether 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3, Myrj 51 9005-00-9, Polyoxyethylene stearyl ether 9005-08-7, Polyethylene glycol distearate 9005-32-7, Alginic acid 9005-64-5, Polysorbate 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, Polyglyceryl oleate 9011-21-6 9011-29-4 9014-67-9, Aloxiprin 9016-45-9 9062-73-1, Polyethylene glycol sorbitan laurate 9062-90-2, Polyethylene glycol sorbitan oleate 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic acid, biological studies **10043-35-3**, **Boric acid**, biological studies 10238-21-8 10262-69-8, Maprotiline 10457-90-6, Bromperidol 10540-29-1, Tamoxifen 11140-04-8, Imwitor 988 12633-72-6, Amphotericin 12772-47-3, Pentaerythritol oleate 13292-46-1, Rifampin 13392-28-4, Rimantadine 13523-86-9 **13655-52-2**, Alprenolol 14028-44-5, Amoxapine 14611-51-9, Selegiline 14808-79-8, Sulfate, biological studies 15307-86-5, Diclofenac 15574-96-6, Pizotifen 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15686-83-6, Pyrantel 15687-27-1, Ibuprofen 16110-51-3, Cromoglicic acid 16773-42-5, Ornidazole 17560-51-9, Metolazone 17617-23-1, Flurazepam 18016-80-3, Lysuride 18507-89-6, Decoquinate 18559-94-9, Albuterol 19216-56-9, Prazosin 19387-91-8, Tinidazole 19794-93-5, Trazodone 20594-83-6, Nalbuphine 21187-98-4, Gliclazide 21256-18-8, Oxaprozin 21645-51-2, Aluminum hydroxide, biological studies 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22071-15-4, Ketoprofen 22131-79-9, Alclofenac 22204-53-1 22232-71-9, Mazindol 22494-42-4, Diflunisal 22882-95-7, Isopropyl linoleate 22916-47-8, Miconazole 22994-85-0, Benznidazole 23031-25-6, Terbutaline 23110-15-8, Fumagillin 23288-49-5, Probucol 23593-75-1, Clotrimazole 24219-97-4, Mianserin 25339-99-5, Sucrose monolaurate 25523-97-1, Dexchlorpheniramine 25614-03-3, Bromocriptine 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 25812-30-0,

Gemfibrozil 25953-19-9, Cefazolin 26097-80-3, Cambendazole 26171-23-3, Tolmetin 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 26658-19-5, Sorbitan tristearate 26839-75-8, Timolol 26912-41-4D, Polyethylene glycol caprate, glycerides 27195-16-0, Sucrose distearate 27203-92-5, Tramadol 27220-47-9, Econazole 27321-96-6, Polyethylene glycol cholesterol 27638-00-2, Glyceryl dilaurate 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28911-01-5, Triazolam 28981-97-7, Alprazolam 29094-61-9, Glipizide 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29767-20-2, Teniposide 30299-08-2, Clinofibrate 30909-51-4, Flupentixol decanoate 31431-39-7, Mebendazole 31692-85-0, Glycofurol 33419-42-0, Etoposide 33671-46-4, Clotiazepam 33940-98-6 34406-66-1, Nikkol Decaglyn 1L 34580-13-7, Ketotifen 34911-55-2, Bupropion 36322-90-4, Piroxicam 36330-85-5, Fenbufen 36354-80-0, Glyceryl dicaprylate 36531-26-7, Oxantel 36894-69-6, Labetalol 37148-27-9, Clenbuterol 37220-82-9, ARLACEL 186 37318-31-3, Crodesta F-160 37321-62-3, Lauroglycol FCC 37517-30-9, Acebutolol 38194-50-2, Sulindac 38304-91-5, Minoxidil 38821-53-3, Cephradine 39366-43-3, Magnesium aluminum hydroxide 41340-25-4, Etodolac 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42766-91-6, Nikkol DHC 43200-80-2, Zopiclone 43210-67-9, Fenbendazole 50679-08-8, Terfenadine 51192-09-7, Nikkol TMGO 5 51264-14-3, Amsacrine 51322-75-9, Tizanidine 51384-51-1, Metoprolol 51481-61-9, Cimetidine 51803-78-2 51938-44-4, Sorbitan sesquistearate 52081-33-1, Mitomycins 52468-60-7, Flunarizine 52504-24-2, Softigen 767 52581-71-2, Volpo 3 52942-31-1, Etoperidone 53168-42-6, Myvacet 9-45 53179-11-6, Loperamide 53230-10-7, Mefloquine 53716-50-0, Oxfendazole 53988-07-1, Glyceryl dicaprate 54029-12-8, Ricobendazole 54143-55-4, Flecainide 54340-58-8, Meptazinol 54392-26-6, Sorbitan monoisostearate 54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 55268-74-1, Praziquantel 55985-32-5, Nicardipine 57107-95-6 57307-93-4, Pentaerythritol caprylate 57801-81-7, Brotizolam 57808-66-9, Domperidone 58581-89-8, Azelastine 59467-70-8, Midazolam 59729-33-8, Citalopram 60142-96-3, Gabapentin 60607-34-3, Oxatomide 60719-84-8, Amrinone 61318-90-9, Sulconazole 61379-65-5, Rifapentine 61869-08-7 62013-04-1, Dirithromycin 62571-86-2, Captopril 63590-64-7, Terazosin 63675-72-9, Nisoldipine 64211-45-6, Oxiconazole 64221-86-9, Imipenem 64840-90-0, Eperisone 64872-76-0, Butoconazole 65271-80-9, Mitoxantrone 65277-42-1, Ketoconazole 65899-73-2, Tioconazole 66085-59-4, Nimodipine 66357-35-5, Ranitidine 67227-56-9, Fenoldopam 67352-02-7 67915-31-5, Terconazole 68506-86-5, Vigabatrin 68844-77-9, Astemizole 68958-64-5, Polyethylene glycol glyceryl trioleate

68993-42-0D, Polyethylene glycol caprylate, glycerides 69070-98-0 69756-53-2, Halofantrine 70458-96-7, Norfloxacin 71125-38-7, Meloxicam 71486-22-1, Vinorelbine 72432-03-2, Miglitol 72509-76-3, Felodipine 72559-06-9, Rifabutin 72803-02-2, Darodipine 73590-58-6, Omeprazole 74011-58-8, Enoxacin 74103-06-3, Ketorolac 74191-85-8, Doxazosin 74504-64-6, Polyglyceryl laurate 75330-75-5, Lovastatin 75695-93-1, Isradipine 75706-12-6, Leflunomide
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 75847-73-3, Enalapril 76009-37-5 76547-98-3, Lisinopril 76584-70-8 76824-35-6, Famotidine 76963-41-2, Nizatidine 77671-31-9, Enoximone 78273-80-0, Roxatidine 79617-96-2, Sertraline 79665-93-3, Nikkol Decaglyn 1O 79665-94-4 79794-75-5, Loratadine 80214-83-1, Roxithromycin 81093-37-0, Pravastatin 81098-60-4, Cisapride 81103-11-9, Clarithromycin 82159-09-9, Epalrestat 82419-36-1, Ofloxacin 82626-48-0, Zolpidem 82664-20-8, Flurithromycin 83366-66-9, Nefazodone 83799-24-0, Fexofenadine 83881-51-0, Cetirizine 83905-01-5, Azithromycin 84057-84-1, Lamotrigine 84449-90-1, Raloxifene 84625-61-6, Itraconazole 85441-61-8, Quinapril 85721-33-1, Ciprofloxacin 86386-73-4, Fluconazole 86541-75-5, Benazepril 87718-67-0, Spiramycins 87848-99-5, Acrivastine 88150-42-9, Amlodipine 89778-26-7, Toremifene 91161-71-6, Terbinafine 91374-21-9, Ropinirole 91714-94-2, Bromfenac 93106-60-6, Enrofloxacin 93390-81-9, Fosphenytoin 93413-69-5, Venlafaxine 93479-97-1, Glimepiride 93957-54-1, Fluvastatin 94423-19-5 94555-53-0 95233-18-4, Atovaquone 97322-87-7, Troglitazone 97682-44-5, Irinotecan 98048-97-6, Fosinopril 98079-51-7 98913-68-9, Pentaerythritol isostearate 99614-02-5, Ondansetron 100986-85-4, Levofloxacin 101828-21-1, Butenafine 102051-00-3, Nikkol Decaglyn 3O 103177-37-3, Pranlukast 103577-45-3, Lansoprazole 103628-46-2, Sumatriptan 104632-26-0, Pramipexole 105979-17-7, Benidipine 106133-20-4, Tamsulosin 106266-06-2, Risperidone 106392-12-5, Polyoxyethylene-polyoxypropylene block copolymer 106650-56-0, Sibutramine 107753-78-6, Zafirlukast 109889-09-0, Granisetron 110871-86-8, Sparfloxacin 111025-46-8, Pioglitazone 111974-69-7, Quetiapine 113665-84-2, Clopidogrel 114798-26-4, Losartan 115103-54-3, Tiagabine 115956-12-2, Dolasetron 117976-89-3, Rabeprazole 119914-60-2, Grepafloxacin 120014-06-4, Donepezil 121548-04-7, Gelucire 44/14 121548-05-8, Gelucire 50/13 121679-13-8, Naratriptan 122320-73-4, Rosiglitazone 123948-87-8, Topotecan 124937-51-5, Tolterodine 127779-20-8, Saquinavir 129497-78-5, Verteporfin 129618-40-2, Nevirapine 132539-06-1, Olanzapine 132875-61-7, Remifentanil 133040-01-4, Eprosartan 133248-87-0, Maisine 134308-13-7, Tolcapone 134523-00-5, Atorvastatin 134678-17-4, Lamivudine

135062-02-1, Repaglinide 136470-78-5, Abacavir 136817-59-9, Delavirdine 137862-53-4, Valsartan 138402-11-6 139264-17-8, Zolmitriptan 139481-59-7, Candesartan 139755-83-2, Sildenafil 144034-80-0, Rizatriptan 144494-65-5, Tirofiban 144701-48-4, Telmisartan 145599-86-6, Cerivastatin 146961-76-4, Alatrofloxacin 147059-72-1, Trovafloxacin 150372-93-3, Glycerox L 150378-17-9, Indinavir 151096-09-2, Moxifloxacin 154598-52-4, Efavirenz 155213-67-5, Ritonavir 156259-68-6, Capmul MCM 158747-02-5, Frovatriptan 158966-92-8, Montelukast 159989-64-7, Nelfinavir 161814-49-9, Amprenavir 169590-42-5, Celecoxib 185069-68-5, Polyglyceryl oleate stearate 301206-59-7 301524-91-4, Captex 810
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

IT 50-70-4, Sorbitol, biological studies 56-81-5, 1,2,3-Propanetriol, biological studies 57-55-6, 1,2-Propanediol, biological studies 64-17-5, Ethanol, biological studies 67-63-0, Isopropanol, biological studies 69-65-8, D-Mannitol 71-36-3, Butanol, biological studies 77-89-4, Acetyl triethylcitrate 77-90-7, Acetyl tributyl citrate 77-93-0, Triethylcitrate 77-94-1, Tributylcitrate 100-51-6, Benzenemethanol, biological studies 102-76-1, Triacetin 105-37-3, Ethyl propionate 105-54-4, Ethyl butyrate 105-60-2, biological studies 106-32-1, Ethyl caprylate 107-21-1, 1,2-Ethanediol, biological studies 115-77-5, biological studies 127-19-5, Dimethylacetamide 502-44-3, 2-Oxepanone 542-28-9, .delta.-Valerolactone 616-45-5, 2-Pyrrolidone 623-84-7, Propylene glycol diacetate 675-20-7, 2-Piperidone 872-50-4, N-Methylpyrrolidone, biological studies 1331-12-0, Propylene glycol monoacetate 2687-91-4, N-Ethylpyrrolidone 2687-94-7 2687-96-9 3068-88-0, .beta.-Butyrolactone 3445-11-2 9002-89-5, Polyvinylalcohol 9003-39-8, Polyvinylpyrrolidone 9004-34-6D, Cellulose, derivs., biological studies 9004-65-3, Hydroxypropyl methylcellulose 9050-36-6, Maltodextrin 12619-70-4D, Cyclodextrin, derivs. 25265-75-2, Butanediol 25322-68-3 25322-69-4, Polypropylene glycol
(solubilizer; pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and triglycerides)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Blair; US 4306981 A 1981 HCA
(2) Hauer; US 5342625 A 1994 HCA
(3) Story; US 4944949 A 1990 HCA

IT **6452-71-7**, Oxprenolol **10043-35-3, Boric acid**, biological studies **13655-52-2**, Alprenolol
(pharmaceutical compns. contg. hydrophobic therapeutic agents and carriers contg. ionizing agents and surfactants and

triglycerides)
RN 6452-71-7 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-(9CI) (CA INDEX NAME)



RN 10043-35-3 HCA
CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 13655-52-2 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-(9CI) (CA INDEX NAME)



L29 ANSWER 4 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 127:50692 HCA
ED Entered STN: 22 Jul 1997
TI Chiral intramolecular amine-borane complexes as reducing agents for prochiral ketones
AU Toumelin, Jean-Brice Le; Baboulene, Michel
CS Laboratoire des IMRCP, UMR 5623 (CNRS), Universite P. Sabatier, Toulouse, 31062, Fr.
SO Tetrahedron: Asymmetry (1997), 8(8), 1259-1265
CODEN: TASYE3; ISSN: 0957-4166
PB Elsevier
DT Journal
LA English
CC 29-4 (Organometallic and Organometalloidal Compounds)
OS CASREACT 127:50692

GI




I




II

AB A new family of chiral amine-borane complexes, the N-spiroazaborolidines I, were synthesized from reaction of allylaminoethanol II (e.g., R1 = H, Me, R2 = Me, Ph) with R3B(OH)2 (R3 = Me, Ph, H) followed by cyclization with borane dimethylsulfide. I are stable, convenient to use, and are excellent reducing agents of prochiral ketones (yieldreduction .gtoreq. 95%). However, poor enantioselectivity was obtained (ee .ltoreq. 38%). The configuration of these mols. (cis position between Baza and the substituent on the Boxaza), unfavorable for a good approach of the ketone, is a possible explanation. These results show the importance of the stereochem. of the N atom in amine-borane complexes for asym. synthesis.

ST spiroazaborolidine prepn redn prochiral ketone; allylaminoethanol cyclization trimethylboroxin phenylboronic acid; oxazaborolidine prepn spiro cyclization borane dimethylsulfide

IT Reducing agents
(chiral intramol. N-spiroazaborolidine complexes as reducing agents for prochiral ketones)

IT Ketones, reactions
(chiral intramol. N-spiroazaborolidine complexes as reducing agents for prochiral ketones)

IT Alcohols, preparation
(chiral, amino; prepn. and cyclization with trimethylboroxine or phenylboronic acid to give oxazaborolidines)

IT Asymmetric synthesis and induction
Configuration
Stereochemistry

(of chiral intramol. N-spiroazaborolidine complexes as reducing agents for prochiral ketones)

IT 191173-29-2P 191173-30-5P 191173-31-6P 191173-32-7P
191173-33-8P
(prepn. and reaction with borane dimethylsulfide to give N-spiroazaborolidine)

IT **191173-27-0P**
(prepn. and reactions with trimethylboroxin or phenylboronic acid to give oxazaborolidines)

IT **108903-01-1P 191173-28-1P**
(prepn. and reactions with trimethylboroxine or phenylboronic acid to give oxazaborolidines)

IT 191173-34-9P 191173-35-0P 191173-36-1P 191173-37-2P
191173-38-3P 191173-39-4P 191173-40-7P 191173-41-8P
(prepn. and use as reducing agent for conversion of prochiral ketones to alcs.)

IT 598-75-4P 1445-91-6P 1517-69-7P 1565-74-8P 14898-86-3P
(prepn. of)

IT 492-41-1
(reactions with allyl bromide to give chiral allyl aminoethanol)

IT 15448-47-2, reactions 20780-53-4
(reactions with allylamine to give chiral allyl aminoethanol)

IT 106-95-6, Allyl bromide, reactions
(reactions with amino alc. to give allyl aminoethanol)

IT 107-11-9, Allylamine
(reactions with chiral epoxides to give allyl aminoethanol)

IT 98-80-6, Phenylboronic acid 823-96-1, Trimethylboroxin
13780-71-7, **Boric acid** (HB(OH)2)
(reactions with trimethylboroxin or phenylboronic acid with amino alcs. to give oxazaborolidines)

IT 93-55-0, Ethyl phenyl ketone 98-86-2, Acetophenone, reactions
563-80-4, 3-Methyl-2-butanone 611-70-1, Isopropyl phenyl ketone
(redn. by amine-borane complexes to alc.)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Baboulene, M; Bull Soc Chim Fr, part II 1980, P565 HCA
(2) Berenguer, R; Tetrahedron:Asymmetry 1994, V5(2), P165 HCA
(3) Biosym; Module Insight Discover 95
(4) Brown, H; Acc Chem Res 1992, V25, P16 HCA
(5) Burns, B; Tetrahedron:Asymmetry 1994, V5(5), P801 HCA
(6) Cai, D; Tetrahedron Lett 1993, V34(20), P3243 HCA
(7) Chiodi, O; Tetrahedron Lett 1996, V37(1), P39 HCA
(8) Corey, E; J Am Chem Soc 1987, V109, P5551 HCA
(9) Corey, E; J Am Chem Soc 1987, V109, P7925 HCA
(10) Corey, E; J Am Chem Soc 1994, V116, P3151 HCA
(11) Corey, E; Tetrahedron Lett 1992, V33(24), P3429 HCA
(12) Deloux, I; Chem Review 1993, V93, P763
(13) Douglas, A; Tetrahedron:Asymmetry 1996, V7(5), P1303 HCA

(14) Dubois, L; Tetrahedron:Asymmetry 1995, V6(5), P1097 HCA
(15) Eleveld, M; Tetrahedron Lett 1986, V27(5), P635 HCA
(16) Ferey, V; Angew Chem Int Ed 1996, V35(4), P430 HCA
(17) Grundon, M; Tetrahedron Lett 1976, V4, P295
(18) Lane, C; Aldrichimica Acta 1973, V6(3), P51 HCA
(19) Le Toumelin, J; Langmuir 1996, V12, P2128 HCA
(20) Midland, M; J Org Chem 1992, V57, P2953 HCA
(21) Nevalainen, V; Tetrahedron:Asymmetry 1994, V5(2), P289 HCA
(22) Nevalainen, V; Tetrahedron:Asymmetry 1995, V6(6), P1431 HCA
(23) Nevalainen, V; Tetrahedron:Asymmetry 1996, V7(5), P1449 HCA
(24) Pelter, A; Borane Reagents 1988, P125
(25) Periasamy, M; J Chem Soc Perkin Trans I 1995, P427 HCA
(26) Polivka, Z; Collect Czech Chem Commun 1970, V35, P1147 HCA
(27) Tiahuexi, H; Tetrahedron:Asymmetry 1992, V3(9), P1145
(28) Tiahuexi, H; Tetrahedron:Asymmetry 1994, V5(8), P1579
(29) Wallbaum, S; Tetrahedron:Asymmetry 1992, V3(12), P1475 HCA
(30) Zaidlewicz, M; Reports IMEBORON IX 1996, P89

IT **191173-27-0P**
(prepn. and reactions with trimethylboroxin or phenylboronic acid to give oxazaborolidines)

RN 191173-27-0 HCA

CN 2-Propanol, 1-(2-propenylamino)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **108903-01-1P 191173-28-1P**
(prepn. and reactions with trimethylboroxine or phenylboronic acid to give oxazaborolidines)

RN 108903-01-1 HCA

CN Benzenemethanol, .alpha.-[1-(2-propenylamino)ethyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 191173-28-1 HCA
CN Benzenemethanol, .alpha.-[(2-propenylamino)methyl]-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L29 ANSWER 5 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 124:116342 HCA
ED Entered STN: 21 Feb 1996
TI Selective extraction and separation of optical isomers of .beta.-amino alcohol or 1,2-diol
IN Nishizawa, Hideyuki; Abe, Yoshihiro
PA Japan
SO Jpn. Kokai Tokkyo Koho, 10 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C07B057-00
ICS C07B057-00; C07B063-00; C07C031-20
ICI C07M007-00
CC 21-3 (General Organic Chemistry)
Section cross-reference(s): 25, 63
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 07242569 | A2 | 19950919 | JP 1994-58068 | 19940303 |
| JP 3467709 | B2 | 20031117 | | |

PRAI JP 1994-58068 19940303
CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|
| JP 07242569 | ICM | C07B057-00 |
| | ICS | C07B057-00; C07B063-00; C07C031-20 |
| | ICI | C07M007-00 |

OS MARPAT 124:116342
AB A mixt. of .beta.-amino alc. optical isomers HOCR11R12C(XH)R13R14 (I; X = NH, NR101; wherein R101 = org. group; R12 - R14 = H, org.

group; at least one of the C atoms bonded to R12 and R13 is an asym. C atom), useful as drugs or its intermediates, is subjected to the liq.-liq. sepn. and extn. between an org. phase and an aq. phase in the presence of **boric acid** and/or **boric acid** salt and an optically active 1,2-diol (resolving agent) or a .beta.-amino alc. HOR22R21CC(NR25R26)R23R24 (R21 = org. group; R22 - R26 = H, or org. group; at least one of the C atoms bonded to R21 and R23 is an asym. C atom) and one of said .beta.-amino alc. optical isomers is selectively extd. and sepd. to one of the liq. phases. Preferably said 1,2-diol is a tartaric acid ester, preferably C alkyl, benzyl, or cyclohexyl ester and said .beta.-amino alc. is pindolol, propranolol, alprenolol, chlorprenaline, bunitrolol, allotinorol, atenolol, and terbutaline. Conversely, a mixt. of 1,2-diol optical isomers is subjected to the liq.-liq. sepn. and extn. between an org. phase and an aq. phase in the presence of **boric acid** and/or **boric acid** salt and an optically active .beta.-amino alc. I (resolving agent) and one of said 1,2-diol optical isomers is selectively extd. and sepd. to one of the liq. phases. Thus, CHCl3, didodecyl L-tartrate (resolving agent, prepn. given) (100 mM in CHCl3), 100 mM **boric acid** soln., and (.+-.)-pindolol (0.5 mM in the total vol. of the 2 liq. phases) were shaken well. The distribution ratio of each optical isomer in the 100 mM **boric acid** layer was 0.790.+-.0.013 and 1.730.+-.0.026 and the sepn. coeff. was 2.19 as compared to 0.75 and 1.75 for a 100 mM acetic acid buffer and a 100 mM phosphoric acid buffer, resp.

ST beta amino alc resoln; **boric acid** soln selective extn sepn; optically active diol resolving agent; tartaric acid ester resolving agent

IT Resolution
(resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT Alcohols, preparation
(amino, resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT **10043-35-3P**, **Boric acid**, preparation
**13840-56-7P**, Sodium borate
(aid for resolving agent; resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT 87-69-4, L-Tartaric acid, reactions 112-53-8, Dodecyl alcohol
(esterification of tartaric acid with alcs.)

IT 525-66-6P, Propranolol 13523-86-9P, Pindolol **13655-52-2P**, Alprenolol

(resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT 3811-25-4 23031-25-6, Terbutaline 29122-68-7, Atenolol 34915-68-9, Bunitrolol 68377-92-4, Arotinolol
(resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT 87-92-3P, Dibutyl L-tartrate 622-00-4P, Dibenzyl L-tartrate 15785-59-8P 66584-29-0P 77459-97-3P
(resolving agent; resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT 56-23-5, Carbontetrachloride, uses 67-66-3, Chloroform, uses 71-36-3, n-Butanol, uses 71-55-6, 1,1,1-Trichloroethane 75-09-2, Dichloromethane, uses 107-06-2, 1,2-Dichloroethane, uses 108-88-3, Toluene, uses 141-78-6, Ethyl acetate, uses
(solvent; resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

IT **10043-35-3P**, **Boric acid**, preparation
**13840-56-7P**, Sodium borate
(aid for resolving agent; resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)

RN 10043-35-3 HCA
CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 13840-56-7 HCA
CN Boric acid (H3BO3), sodium salt (8CI, 9CI) (CA INDEX NAME)



●x Na

IT **13655-52-2P**, Alprenolol
(resoln. of .beta.-amino alc. by selective liq.-liq. extn. and sepn. of optical isomers of .beta.-amino alc. in presence of optically active 1,2-diol and **boric acid**)
RN 13655-52-2 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]- (9CI) (CA INDEX NAME)



L29 ANSWER 6 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 123:198072 HCA
ED Entered STN: 07 Oct 1995
TI Enantioselective distribution of amino-alcohols in a liquid-liquid two-phase system containing dialkyl L-tartrate and **boric acid**
AU Abe, Yoshihiro; Shoji, Tomoko; Kobayashi, Michi; Qing, Wang; Asai, Naoko; Nishizawa, Hideyuki
CS Kyoritsu Coll. Pharmacy, Tokyo, 105, Japan
SO Chemical & Pharmaceutical Bulletin (1995), 43(2), 262-5
CODEN: CPBTAL; ISSN: 0009-2363
PB Pharmaceutical Society of Japan
DT Journal
LA English
CC 22-3 (Physical Organic Chemistry)
AB Racemic amino alcs. such as pindolol, propranolol, alprenolol and bucumolol enantiomers exhibited different distribution behaviors in a two-phase system consisting of a chloroform soln. of didodecyl L-tartrate and an aq. soln. of **boric acid.** It seemed that a borate complex of the 1,2-diol group of the tartrate and the amino alc. was formed in the system. In the case of pindolol, one enantiomer was preferentially extd. into the org. phase (.times.2.20) at equil.
ST enantioselective distribution amino alc liq liq; tartrate **boric acid** resoln amino alc
IT Resolution
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)
IT Alcohols, processes
(amino, enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and

**boric acid**)

IT 87-91-2, Diethyl L-tartrate 608-68-4, Dimethyl L-tartrate 622-00-4, Dibenzyl L-tartrate **10043-35-3**, **Boric acid (H3BO3)**, uses
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)

IT 87-92-3P, Dibutyl L-tartrate 2217-14-3P 15785-59-8P 66584-29-0P 77459-97-3P
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)

IT 525-66-6, Propranolol 13523-86-9, Pindolol **13655-52-2** 58409-59-9, Bucumolol
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)

IT **10043-35-3**, **Boric acid (H3BO3)**, uses
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)

RN 10043-35-3 HCA

CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **13655-52-2**
(enantioselective distribution of amino alcs. in a liq.-liq. two-phase system contg. dialkyl L-tartrate and **boric acid**)

RN 13655-52-2 HCA

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]- (9CI) (CA INDEX NAME)



L29 ANSWER 7 OF 10 HCA COPYRIGHT 2005 ACS on STN

AN 121:187403 HCA

ED Entered STN: 15 Oct 1994
TI Introduction of migration indices for identification: chiral separation of some .beta.-blockers by using cyclodextrins in micellar electrokinetic capillary chromatography
AU Siren, Heli; Jumppanen, Juho H.; Manninen, Kirsi; Riekkola, Marja-Liisa
CS Dep. Chem., Univ. Helsinki, Finland
SO Electrophoresis (1994), 15(6), 779-84
CODEN: ELCTDN; ISSN: 0173-0835
DT Journal
LA English
CC 64-3 (Pharmaceutical Analysis)
Section cross-reference(s): 1
AB Because of the different physiol. impact that stereoisomers may have, it is often vital to sep. these forms from one another. Because of their structural similarity, the sepn. is usually difficult to achieve and zones may elute very close to each other. This is a particular problem in capillary electrophoresis, where the repeatability of abs. migration times is fairly poor, mainly due to the irreproducibility of the electroosmotic flow. The sepn. is usually repeatable, however, and when the disturbing effects are eliminated by using a migration index system incorporating two marker compds. the identification of the enantiomers becomes extremely good. Relative std. deviation (RSD) values less than 0.1% for the migration index of each enantiomer were obtained in both intra-day and day-to-day (6 days) studies. The best sepn. was achieved with the electrolyte soln. made of 40 mM borate, 32 mM sodium dodecyl sulfate (SDS), 12 mM .beta.-cyclodextrin (.beta.-CD), and 6 mM .alpha.-cyclodextrin (.alpha.-CD) at pH 9.3.
ST beta blocker chiral sepn; micellar electrokinetic capillary chromatog beta blocker
IT Resolution
(chromatog., migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)
IT Chromatography, column and liquid
(electrokinetic micellar, capillary, migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)
IT Adrenergic antagonists
(.beta.-, migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)
IT 525-66-6, (.+-.)-Propranolol 4199-09-1, (-)-Propranolol 5051-22-9, (+)-Propranolol **13655-52-2**, (.+-.)-Alprenolol **23846-71-1**, (-)-Alprenolol **23846-72-2**, (+)-Alprenolol 29122-68-7, (.+-.)-Atenolol 56715-13-0, (+)-Atenolol 93379-54-5, (-)-Atenolol

(migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)

IT 151-21-3, Sodium dodecyl sulfate, analysis 7585-39-9, .beta.-Cyclodextrin 10016-20-3, .alpha.-Cyclodextrin **10043-35-3, Boric acid**, analysis
(migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)

IT **13655-52-2**, (.+-.)-Alprenolol **23846-71-1**, (-)-Alprenolol **23846-72-2**, (+)-Alprenolol
(migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)

RN 13655-52-2 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 23846-71-1 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 23846-72-2 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **10043-35-3, Boric acid**, analysis
(migration indexes in chiral sepn. of .beta.-blockers using cyclodextrins in micellar electrokinetic capillary chromatog.)
RN 10043-35-3 HCA
CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)




L29 ANSWER 8 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 120:200438 HCA
ED Entered STN: 16 Apr 1994
TI Controlled-release transdermal pharmaceuticals containing cryogels
IN Wood, Louis L.; Calton, Gary J.
PA SRCHEM Inc., USA
SO U.S., 15 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61L015-16
INCL 424447000
CC 63-6 (Pharmaceuticals)
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | US 5260066 | A | 19931109 | US 1992-821627 | 19920116 |
| | US 5288503 | A | 19940222 | US 1992-899369 | 19920616 |
| PRAI | US 1992-821627 | A3 | 19920116 | | |

CLASS

| PATENT NO. | CLASS | PATENT FAMILY CLASSIFICATION CODES |
|---|---|---|

| | | |
|---|---|---|
| US 5260066 | ICM | A61L015-16 |
| | INCL | 424447000 |
| US 5260066 | NCL | 424/447.000; 424/443.000; 424/445.000; 424/486.000 |
| US 5288503 | NCL | 424/497.000; 424/078.100; 424/078.120; 424/078.130 |

AB A controlled-release transdermal pharmaceutical contg. therapeutic agents in a poly(vinyl alc.) (I) cryogel is disclosed. A slurry of 11.0 mg ciprofloxacin.HCl (II) and 200 mg 10% I was warmed to 50-60.degree. to obtain a clear homogeneous soln. The soln. was then placed in a mold and subjected to 6 freeze-thaw cycles to give a white opaque elastomeric cryogel having 15mm diam. and 0.5mm thickness. The release of II from the gel in 0.9% NaCl was 74% in th 1st 4 hs and it was const. in the subsequent 5-24 hs.

ST controlled release transdermal pharmaceutical cryogel; ciprofloxacin polyvinyl alc cryogel transdermal pharmaceutical

IT Vitamins
(J, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Manganins (proteins)
Thyroglobulins
(controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Quaternary ammonium compounds, biological studies
(alkylbenzyldimethyl, chlorides, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Animal growth regulators
(blood platelet-derived growth factors, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Agglutinins and Lectins
(cecropins, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Gels
(cryogenic, controlled-release transdermal pharmaceuticals 60contg. therapeutic agents and)

IT Pharmaceutical natural products
(digitalis, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Animal growth regulators
(epithelium-derived growth factors, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Fatty acids, biological studies
(essential, controlled-release transdermal pharmaceuticals contg. cryogels and)

IT Pharmaceutical dosage forms
(transdermal, controlled-release, cryogels and therapeutic agents in)

IT 50-00-0, Formaldehyde, biological studies 50-02-2, Dexamethasone 50-06-6, biological studies 50-07-7, Mitomycin C 50-18-0, Cytoxan 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-56-6, Oxytocin, biological studies 50-76-0, Actinomycin D 50-78-2 50-81-7, Vitamin C, biological studies 51-05-8, Procaine hydrochloride 51-21-8, 5-Fluorouracil 51-34-3, Scopolamine 51-41-2, Levarterenol 51-43-4, Epinephrine 51-48-9, Thyroxine, biological studies 51-64-9, Dextroamphetamine 51-77-4, Gefarnate 52-53-9, Verapamil 52-86-8, Haloperidol 53-03-2, Prednisone 53-06-5, Cortisone 54-31-9, Furosemide 54-42-2, Idoxuridine 54-85-3, Isoniazide 54-91-1, Pipobroman 55-63-0 56-40-6, Glycine, biological studies 56-41-7, Alanine, biological studies 56-45-1, Serine, biological studies 56-54-2, Quinidine 56-75-7, Chloramphenicol 56-84-8, Aspartic acid, biological studies 56-85-9, Glutamine, biological studies 56-86-0, Glutamic acid, biological studies 56-87-1, Lysine, biological studies 57-27-2, Morphine, biological studies 57-41-0, Phenytoin 57-42-1, Meperidine 57-66-9, Probenecid 57-92-1, Streptomycin, biological studies 58-08-2, biological studies 58-14-0, Pyrimethamine 58-32-2, Dipyridamole 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-74-2, Papaverine 58-93-5 59-01-8, Kanamycin 59-05-2, Methotrexate 59-33-6 59-46-1, Procaine 59-87-0 59-92-7, Levodopa, biological studies 60-54-8, Tetracycline 61-25-6, Papaverine hydrochloride 61-32-5, Methicillin 61-33-6, preparation 61-72-3, Cloxacillin 61-90-5, L-Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-97-5, Diphemanil 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 64-17-5, Ethanol, biological studies 65-49-6 66-79-5, Oxacillin 67-63-0, Isopropanol, biological studies 68-88-2, Hydroxyzine 69-23-8, Fluphenazine 69-43-2, Prenylamine lactate 69-53-4, Ampicillin 69-72-7, biological studies 70-00-8, Trifluridine 70-30-4, Hexachlorophene 71-00-1, Histidine, biological studies 72-19-5, Threonine, biological studies 72-44-6, Methaqualone 72-69-5 73-22-3, Tryptophan, biological studies 73-32-5, Isoleucine, biological studies 73-48-3 74-79-3, Arginine, biological studies 76-99-3, Methadone 77-07-6, Levorphanol 77-19-0, Dicyclomine 77-21-4, Glutethimide 78-11-5, Pentaerythritol tetranitrate 79-57-2, Oxytetracycline 81-23-2, Dehydrocholic acid 83-88-5, Vitamin G, biological studies 83-98-7, Orphenadrine 85-79-0, Dibucaine 86-21-5, Pheniramine 86-22-6, Brompheniramine 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 90-82-4, Pseudoephedrine 91-81-6, Tripelennamine 94-09-7, Benzocaine 95-27-2, Dimazole 100-92-5, Mephentermine 101-31-5, Hyoscyamine 108-46-3, 1,3-Benzenediol, biological studies 112-38-9, Undecylenic acid 113-15-5,

Ergotamine 113-92-8 114-07-8, Erythromycin 115-38-8, Methylphenobarbital 118-23-0, Bromodiphenhydramine 118-42-3, Hydroxychloroquine 121-54-0 122-09-8, Phentermine 122-11-2, Sulfadimethoxine 125-29-1, Hydrocodone 125-71-3, Dextromethorphan 126-07-8, Griseofulvin 127-33-3, Demeclocycline 127-69-5, Sulfisoxazole 128-62-1, Noscapine 129-16-8, Mercurochrome 132-17-2 133-15-3 133-67-5, Trichlormethiazide 136-96-9 137-58-6, Lidocaine 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-82-3, Melphalan 151-21-3, Sodium lauryl sulfate, biological studies 153-61-7, Cephalothin 154-21-2 298-57-7, Cinnarizine 300-62-9, Amphetamine 302-17-0, Chloral hydrate 302-79-4, Retinoic acid 303-81-1, Novobiocin 303-98-0 318-98-9 359-83-1, Pentazocine 361-37-5, Methysergide 389-08-2, Nalidixic acid 395-28-8, Isoxsuprine 437-38-7, Fentanyl 439-14-5, Diazepam 447-41-6 466-99-9, Hydromorphone 469-62-5, Propoxyphene 471-53-4, Glycyrrhetic acid 479-18-5, Diprophylline 486-12-4, Triprolidine 496-67-3, Bromovalerylurea 514-65-8, Biperiden 515-64-0, Sulfisomidine 525-66-6, Propranolol 554-13-2, Lithium carbonate 562-10-7 564-25-0, Doxycycline 569-65-3, Meclizine 634-03-7, Phendimetrazine 645-05-6, HMM 668-94-0 671-16-9, Procarbazine 770-05-8, Octopamine hydrochloride 777-11-7, Haloprogin 804-10-4 807-38-5, Fluocinolone 835-31-4, Naphazoline 914-00-1, Methacycline 940-69-2, Vitamin N 1018-71-9, Pyrrolnitrin 1066-17-7, Colistin 1070-11-7 1115-84-0, Vitamin U 1172-18-5, Flurazepam hydrochloride 1319-77-3, Cresol 1319-82-0, Aminocaproic acid 1333-08-0, Ethyl aminobenzoate 1333-73-9, Sodium borate 1340-08-5, Vitamin P 1394-02-1, Trichomycin 1397-89-3, Amphotericin B 1400-61-9, Nystatin 1403-66-3, Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-11-7, Polymyxin 1406-16-2, Vitamin D 1406-18-4, Vitamin E 1407-73-4, Vitamin T 1538-09-6 1668-19-5, Doxepin 1695-77-8, Spectinomycin 1766-91-2, Penflutizide 1982-36-1, Homochlorcyclizine hydrochloride 1982-37-2, Methdilazine 2011-67-8, Nimetazepam 2013-58-3, Meclocycline 2020-25-9 2022-85-7, Flucytosine 2338-37-6, Levoproproxyphene 2398-96-1, Tolnaftate 2751-09-9, Troleandomycin 2751-68-0 3116-76-5, Dicloxacillin 3485-14-1 3562-84-3, Benzbromarone 3737-09-5, Disopyramide 3922-90-5, Oleandomycin 4205-90-7, Clonidine 4299-60-9, Sulfisoxazole diolamine 4342-03-4, DTIC 4697-36-3, Carbenicillin 5536-17-4, Vidarabine 5588-33-0, Mesoridazine **6452-73-9**, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6834-98-6, Pentamycin 7195-27-9, Mefruside 7237-81-2, Hepronicate 7440-22-4D, Silver, salts 7440-45-1D, Cerium, salts 7440-66-6D, Zinc, salts 7487-94-7, Mercuric chloride, biological studies 7542-37-2 7722-64-7, Potassium

permanganate 8017-57-0, Trisulfapyrimidine
(controlled-release transdermal pharmaceuticals contg. cryogels and)

IT 8049-47-6, Pancreatin 9001-09-6, Chymopapain 9001-12-1, Collagenase 9001-73-4, Papain 9001-75-6, Pepsin 9001-90-5, Fibrinolysin 9001-98-3, Rennin 9002-01-1, Streptokinase 9002-07-7, Trypsin 9002-60-2, ACTH, biological studies 9002-64-6, Parathyrin 9002-71-5, Thyrotropin 9002-72-6, Somatotropin 9003-98-9, Desoxyribonuclease 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological studies 9007-12-9, Calcitonin 9015-68-3, Asparaginase 9039-53-6, Urokinase **10043-35-3**, **Boric acid**, biological studies 10118-90-8, Minocycline 10262-69-8, Maprotiline 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 11011-73-7, Bramycin 11056-06-7, Bleomycin 11103-57-4, Vitamin A 11111-12-9, Cephalosporin 12001-76-2, Vitamin B 12001-79-5, Vitamin K 12211-28-8, Sutilains 12607-92-0, Aceglutamide aluminum 12629-01-5, Somatropin 13010-47-4, CCNU 13171-25-0 13265-10-6, Methscopolamine 13292-46-1, Rifampin 13523-86-9, Pindolol 14838-15-4, Phenylpropanolamine 14929-11-4, Simfibrate 15148-80-8, Bupranolol hydrochloride 15307-86-5, Diclofenac 15421-84-8, Trapidil 15663-27-1, cis-Platinum 15686-71-2, Cephalexin 15687-27-1, Ibuprofen 16051-77-7, Isosorbide-5-mononitrate 16110-51-3, Cromolyn 17617-23-1, Flurazepam 17902-23-7, Tegafur 18323-44-9, Clindamycin 18378-89-7, Plicamycin 18472-51-0, Chlorhexidine gluconate 19237-84-4, Prazosin hydrochloride 19504-77-9, Variotin 20153-98-4, Dilazep dihydrochloride 20830-75-5, Digoxin 20830-81-3, Daunorubicin 21593-23-7, Cephapirin 21829-25-4 22071-15-4, Ketoprofen 22161-81-5, S-Ketoprofen 22199-08-2, Silver sulfadiazine 22204-53-1 22494-42-4, Diflunisal 22733-60-4, Siccanin 22916-47-8 23210-58-4, Ifenprodil tartrate 23214-92-8, Doxorubicin 23593-75-1, Clotrimazole 25523-97-1, Dexchlorpheniramine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 25990-43-6, Mepenzolate 26328-04-1, Cinepazide maleate 26787-78-0, Amoxicillin 27060-91-9, Flutazolam 27164-43-8 27321-61-5, 1,2,3-Propanetriolmononitrate 27724-96-5, Cetraxate hydrochloride 27959-26-8, Nicomol 28058-62-0 28088-64-4 28395-03-1 28657-80-9, Cinoxacin 28911-01-5 29122-68-7, Atenolol 29679-58-1, Fenoprofen 29868-97-1, Pirenzepine hydrochloride 29975-16-4, Estazolam 30516-87-1, AZT 30685-43-9, Metildigoxin 32887-01-7, Amdinocillin 33069-62-4, Taxol 33286-22-5, Diltiazem hydrochloride 33419-42-0, VP16 33665-90-6 33671-46-4, Clotiazepam 34444-01-4, Cefamandole 34580-13-7, Ketotifen 34787-01-4 34915-68-9, Bunitrolol 35607-66-0, Cefoxitin 37091-66-0, Azlocillin 37517-28-5,

Amikacin 38194-50-2, Sulindac 38821-53-3, Cephradine 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50972-17-3, Bacampicillin 51384-51-1, Metoprolol 51481-61-9, Cimetidine 51481-65-3, Mezlocillin 51781-21-6, Carteolol hydrochloride 51940-44-4, Pipemidic acid 53608-75-6, Pancrelipase 53902-12-8, Tranilast 53994-73-3, Cefaclor 54527-84-3, Nicardipine hydrochloride 55268-75-2, Cefuroxime 55985-32-5, Nicardipine 56391-56-1, Netilmicin 56392-17-7, Metoprolol tartrate 58001-44-8 59128-97-1, Haloxazolam 59277-89-3, Acyclovir 60925-61-3, Ceforanide 61270-58-4, Cefonicid 61422-45-5, Carmofur 61477-96-1, Piperacillin 62229-50-9, Epidermal growth factor 62683-29-8, CSF 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64221-86-9, Imipenem 64952-97-2, Moxalactam 66676-88-8, Aclacinomycin 67763-96-6, IGF-1 68247-85-8, Peplomycin 68401-81-0, Ceftizoxime 70458-92-3 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73384-59-5, Ceftriaxone 74011-58-8, Enoxacin 78186-34-2, Bisantrene 79217-60-0, Cyclosporin 79660-72-3, Fleroxacin 82009-34-5, Cilastatin 82030-87-3, Somatrem 82410-32-0, Gancyclovir 82419-36-1, Ofloxacin 82657-92-9, Pro-urokinase 83869-56-1, Colony-stimulating factor 2 84137-20-2, 1,2,3-Propanetriolnitrate 85721-33-1, Ciprofloxacin 98079-51-7, Lomefloxacin 100490-36-6 105636-15-5, Suprasec VM 25 118857-69-5D, alkyl derivs. 135968-09-1, RG-CSF 139639-23-9 150977-36-9, Bromelain
(controlled-release transdermal pharmaceuticals contg. cryogels and)

IT **6452-73-9**, Oxprenolol hydrochloride **10043-35-3**, **Boric acid**, biological studies
(controlled-release transdermal pharmaceuticals contg. cryogels and)

RN 6452-73-9 HCA

CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyloxy)phenoxy]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 10043-35-3 HCA
CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



L29 ANSWER 9 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 119:219240 HCA
ED Entered STN: 27 Nov 1993
TI The yeast test: an alternative method for the testing of acute toxicity of drug substances and environmental chemicals
AU Koch, Heinrich P.; Hofeneder, Maria; Bohne, Bernd
CS Inst. Pharm. Chem., Univ. Vienna, Vienna, Austria
SO Methods and Findings in Experimental and Clinical Pharmacology (1993), 15(3), 141-52
CODEN: MFEPDX; ISSN: 0379-0355
DT Journal
LA English
CC 4-1 (Toxicology)
Section cross-reference(s): 1, 10
AB A novel testing procedure has been developed with the aim to replace the traditional LD50 test in vertebrates by a method using a non-pain sensitive organism. Several years of practical experience have proven this method to be a rather quick, simple, inexpensive, outstandingly well reproducible and reliable exptl. technique which yields an est. for the acute toxicity of drugs, environmental chems., solvents, food additives, pesticides, industrial and waste products, and the like. The model is equiv. to the customary LD50 test in mice, rats and other lab. animals. The yeast test, as it has been briefly named, employs ordinary yeast (Saccharomyces cerevisiae) in a thermostatized incubation mixt. with nutrients and trace elements. The test substance is added to this mixt. by increasing concn., and the effect upon the growth rate of the yeast cells is monitored at 30, 90, 150 and 210 min after beginning the expt. by counting the cell no., either in a simple counting chamber under the microscope or, more conveniently, by using an electronic Coulter counter. The effect is expressed as percent growth of the cells in relation to the untreated control. Evaluation of the exptl. data leads to a general toxicity parameter, the mean inhibitory concn. or IC50 value of the compd. under test. Hitherto it was found that the IC50 values of approx. 160 common drugs and other chems. correlate well with the known LD50 values found in animals with the same substances.
ST toxicity drug environmental chem yeast test; Saccharomyces drug environmental chem toxicity test

IT Microorganism growth
(by yeast, in testing of toxicity of drugs and environmental chems.)
IT Saccharomyces cerevisiae
(for testing of toxicity of drugs and environmental chems.)
IT Toxicity
(of drugs and environmental chems., testing of, yeast for)
IT Bioassay
(yeast, for testing of toxicity of drugs and environmental chems.)
IT Quaternary ammonium compounds, biological studies
(alkylbenzyldimethyl, chlorides, toxicity of, testing of, yeast for)
IT Chemicals
(environmental, toxicity of, testing of, yeast for)
IT 121-33-5
(3oxicity of, testing of, yeast test for)
IT 50-00-0, Formaldehyde, biological studies 50-35-1, Thalidomide 50-47-5, Desipramine 50-48-6 50-49-7, Imipramine 50-52-2, Thioridazine 50-54-4, Quinidine sulfate 50-63-5 50-78-2, Acetylsalicylic acid 51-28-5, 2,4-Dinitrophenol, biological studies 51-45-6, Histamine, biological studies 51-60-5, Neostigmine methosulfate 51-83-2, Carbachol 52-53-9, Verapamil 54-11-5, Nicotine 54-21-7, Sodium salicylate 55-48-1, Atropine sulfate 56-25-7, Cantharidine 56-75-7, Chloramphenicol 56-81-5, 1,2,3-Propanetriol, biological studies 57-30-7, Sodium phenobarbitone 57-33-0, Sodium pentobarbitone 57-44-3, Barbitone 57-62-5, Chlortetracycline 58-08-2, Caffeine, biological studies 58-15-1, Amidopyrine 58-55-9, Theophylline, biological studies 58-73-1, Diphenhydramine 58-74-2, Papaverine 59-33-6 59-46-1, Procaine 60-80-0, Phenazone 60-87-7, Promethazine 62-53-3, Aniline, biological studies 62-56-6, Thiourea, biological studies 64-18-6, Formic acid, biological studies 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 66-32-0, Strychnine nitrate 68-88-2, Hydroxyzine 69-72-7, Salicylic acid, biological studies 71-23-8, n-Propanol, biological studies 71-36-3, n-Butanol, biological studies 71-63-6, Digitoxin 73-24-5, Adenine, biological studies 75-04-7, Ethylamine, biological studies 75-07-0, Acetaldehyde, biological studies 75-09-2, Dichloromethane, biological studies 75-50-3, Trimethylamine, biological studies 75-85-4 77-78-1, Dimethyl sulfate 79-09-4, Propionic acid, biological studies 79-11-8, Chloroacetic acid, biological studies 85-79-0, Cinchocaine 87-66-1, Pyrogallol 88-99-3, Phthalic acid, biological studies 89-83-8, Thymol 90-05-1 91-22-5, Quinoline, biological studies 91-64-5, 2H-1-Benzopyran-2-one 94-24-6, Tetracaine 98-01-1, Furfural, biological studies 98-86-2, Acetophenone, biological studies 98-95-3, Nitrobenzene, biological studies 100-02-7, biological

studies 100-17-4, p-Nitroanisole 100-21-0, 1,4-Benzenedicarboxylic acid, biological studies 100-51-6, Benzenemethanol, biological studies 100-52-7, Benzaldehyde, biological studies 100-63-0, Phenylhydrazine 103-84-4, Acetanilide 103-90-2 104-54-1, Cinnamic alcohol 106-44-5, biological studies 106-51-4, p-Benzoquinone, biological studies 107-15-3, 1,2-Ethanediamine, biological studies 107-18-6, 2-Propen-1-ol, biological studies 107-19-7, 2-Propyn-1-ol 108-24-7 108-45-2, 1,3-Benzenediamine, biological studies 108-46-3, 1,3-Benzenediol, biological studies 108-91-8, Cyclohexylamine, biological studies 108-94-1, Cyclohexanone, biological studies 108-95-2, Phenol, biological studies 109-06-8, 2-Picoline 109-73-9, n-Butylamine, biological studies 109-89-7, Diethylamine, biological studies 110-16-7, 2-Butenedioic acid (Z)-, biological studies 110-44-1, Sorbic acid 110-86-1, Pyridine, biological studies 110-89-4, Piperidine, biological studies 110-91-8, Morpholine, biological studies 119-36-8, Methyl salicylate 120-18-3, 2-Naphthalenesulfonic acid 120-51-4, Benzyl benzoate 120-80-9, Pyrocatechol, biological studies 121-57-3, Sulfanilic acid 121-91-5, 1,3-Benzenedicarboxylic acid, biological studies 123-03-5, Cetylpyridinium chloride 123-31-9, Hydroquinone, biological studies 123-75-1, Pyrrolidine, biological studies 124-40-3, Dimethylamine, biological studies 129-67-9, Endothal sodium 130-37-0, Menadione sodium bisulfite 130-95-0, Quinine 135-19-3, 2-Naphthalenol, biological studies 137-58-6, Lidocaine 142-84-7, Di-n-propylamine 144-62-7, Oxalic acid, biological studies 288-32-4, Imidazole, biological studies 299-42-3, L-Ephedrine 302-17-0, Chloralhydrate 303-31-1, .beta.-Thalidomide 327-97-9, Chlorogenic acid 331-39-5, Caffeic acid 364-62-5, Metoclopramide 379-79-3, Ergotamine tartrate 439-14-5, Diazepam 483-18-1, Emetine 513-77-9, Barium carbonate 518-47-8, Sodium fluorescein 525-66-6, Propranolol 541-59-3, 1H-Pyrrole-2,5-dione 542-16-5, Aniline sulfate 630-60-4 630-93-3, Sodium phenytoin 868-18-8, Sodium tartrate 1078-61-1, Dihydrocaffeic acid 1135-24-6, Ferulic acid 1405-87-4, Bacitracin 1491-59-4, Oxymetazoline 1668-19-5, Doxepin 3251-23-8, Cupric nitrate 3724-65-0, Crotonic acid 4170-30-3, Crotonaldehyde 5355-48-6, .beta.-Acetyldigoxin 5511-98-8, .alpha.-Acetyldigoxin 5749-67-7, Calcium carbasalate 5874-97-5 6265-30-1, Norendimide 6319-06-8, Noreximide 7447-39-4, Cupric chloride, biological studies 7632-00-0, Sodium nitrite 7720-78-7, Ferrous sulfate 7722-64-7, Potassium permanganate 7758-98-7, Cupric sulfate, biological studies 7803-49-8, Hydroxylamine, biological studies 10034-93-2, Hydrazine sulfate **10043-35-3**, **Boric acid**, biological studies 10262-69-8 11005-63-3, Strophanthin **13655-52-2**, Alprenolol 14166-26-8, Taglutimide 17617-23-1, Flurazepam 20830-75-5, Digoxin 31555-53-0 35941-65-2 49785-74-2

(toxicity of, testing of, yeast test for)
IT **10043-35-3, Boric acid**, biological studies **13655-52-2**, Alprenolol
(toxicity of, testing of, yeast test for)
RN 10043-35-3 HCA
CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 13655-52-2 HCA
CN 2-Propanol, 1-[(1-methylethyl)amino]-3-[2-(2-propenyl)phenoxy]- (9CI) (CA INDEX NAME)



L29 ANSWER 10 OF 10 HCA COPYRIGHT 2005 ACS on STN
AN 91:47350 HCA
ED Entered STN: 12 May 1984
TI Light-sensitive multicomponent emulsion for diazo materials
IN Kroupa, Jaroslav; Chmatal, Vladimir; Gorgon, Oldrich; Matous, Vladimir
PA Czech.
SO Czech., 3 pp.
CODEN: CZXXA9
DT Patent
LA Czech
IC G03C005-18
CC 74-3 (Radiation Chemistry, Photochemistry, and Photographic Processes)
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI CS 173741 | B | 19770331 | CS 1972-8495 | 19721212 |
| PRAI CS 1972-8495 | A | 19721212 | | |

CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES

CS 173741 IC G03C005-18

AB Dialkylphenolsulfonic acids are cheaper passive coupling components than the commonly used dialkylaminomethylxylenols and give with the usual additives black images of equal brilliance. Thus, a soln. of tartaric acid 3, thiourea 6, 2-hydroxy-3-naphthoic acid .beta.-aminoethylamide 1.9, 3,5-dimethylphenol-4-sulfonic acid 1.8, HCO2H 1.2, and 1-diazo-4-ethylhydroxyethylaminobenzene (ZnCl2 complex) 4.2 g in distd. water 100 mL was coated on a paper support. The dry material was then exposed and developed in NH3 vapors to give a black image on a white background.

ST alkylphenolsulfonic acid coupler diazo copying

IT Diazo process
(dialkylphenolsulfonic acids as passive couplers in)

IT 57-13-6, uses and miscellaneous 62-56-6, uses and miscellaneous 64-18-6, uses and miscellaneous 77-92-9, properties 87-69-4, properties 92-27-3 **105-81-7** 5149-85-9 6014-68-2 **10043-35-3**, uses and miscellaneous 14751-97-4 26889-86-1
(diazo copying materials contg. dialkyphenolsulfonic acid passive couplers and)

IT 14982-58-2 70404-74-9 70404-75-0
(diazo copying materials contg., as passive coupler)

IT **105-81-7 10043-35-3**, uses and miscellaneous
(diazo copying materials contg. dialkyphenolsulfonic acid passive couplers and)

RN 105-81-7 HCA

CN Thiourea, N-(2-hydroxyethyl)-N'-2-propenyl- (9CI) (CA INDEX NAME)



RN 10043-35-3 HCA

CN Boric acid (H3BO3) (6CI, 8CI, 9CI) (CA INDEX NAME)